지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2016.1
- 수록면
- 1,376 - 1,385 (10page)
이용수
초록· 키워드
오류제보하기
Purpose: Infliximab is currently used for the treatment of active Crohn’s disease (CD). We aimed to assess the efficacy and safety of infliximab therapy and to determine the predictors of response in Korean patients with CD.
Materials and Methods: A total of 317 patients who received at least one infliximab infusion for active luminal CD (n=198) and fistulizing CD (n=86) or both (n=33) were reviewed retrospectively in 29 Korean referral centers. Clinical outcomes of induction and maintenance therapy with infliximab, predictors of response, and adverse events were evaluated.
Results: In patients with luminal CD, the rates of clinical response and remission at week 14 were 89.2% and 60.0%, respectively. Male gender and isolated colonic disease were associated with higher remission rates at week 14. In week-14 responders, the probabilities of sustained response and remission were 96.2% and 93.3% at week 30 and 88.0% and 77.0% at week 54, respectively. In patients with fistulizing CD, clinical response and remission were observed in 85.0% and 56.2% of patients, respectively, at week 14. In week-14 responders, the probabilities of sustained response and remission were 94.0% and 97.1%, respectively, at both week 30 and week 54. Thirty-nine patients (12.3%) experienced adverse events related to infliximab. Serious adverse events developed in 19 (6.0%) patients including seven cases of active pulmonary tuberculosis.
Conclusion: Infliximab induction and maintenance therapy are effective and well tolerable in Korean patients with luminal and fistulizing CD. However, clinicians must be aware of the risk of rare yet critical adverse events.
목차
등록된 정보가 없습니다.
참고문헌 (40)
참고문헌 신청
Lichtenstein GR / 2009 / Management of Crohn’s disease in adults / Am J Gastroenterol 104:465~483
Van Assche G / 2010 / The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis / J Crohns Colitis 4:7~27
Tozer PJ / 2009 / Etiology of perianal Crohn’s disease: role of genetic, microbiological, and immunological factors / Inflamm Bowel Dis 15:1591~1598
Ford AC / 2011 / Effcacy of 5-aminosalicylates in Crohn’s disease: systematic review and meta-analysis / Am J Gastroenterol 106:617~629
Khan KJ / 2011 / Effcacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis / Am J Gastroenterol 106:630~642
Van Assche G / 2010 / The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis / J Crohns Colitis 4:7~27
Tozer PJ / 2009 / Etiology of perianal Crohn’s disease: role of genetic, microbiological, and immunological factors / Inflamm Bowel Dis 15:1591~1598
Ford AC / 2011 / Effcacy of 5-aminosalicylates in Crohn’s disease: systematic review and meta-analysis / Am J Gastroenterol 106:617~629
Khan KJ / 2011 / Effcacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis / Am J Gastroenterol 106:630~642
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease
Intestinal research
2023 .01
-
An overview of the role of exclusive enteral nutrition for complicated Crohn’s disease
Intestinal research
2019 .01
-
Second Korean guidelines for the management of Crohn’s disease
Intestinal research
2017 .01
-
Efficacy of Adalimumab in Korean Patients with Crohn’s Disease
Gut and Liver
2016 .01
-
Leukemia propagating cells in Philadelphia chromosome-positive ALL: a resistant phenotype with an adverse prognosis
Blood Research
2018 .01
-
Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn’s Disease Patients
Gut and Liver
2018 .01
-
Korean Children and Adolescents with Crohn's Disease Are More Likely to Present with Perianal Fistulizing Disease at Diagnosis Compared to Their European Counterparts
Pediatric Gastroenterology, Hepatology & Nutrition
2020 .01
-
Effectiveness of transabdominal ultrasonography in predicting clinical relapse of Crohn’s disease
Intestinal research
2024 .01
-
Prospective validation of CD4+CD25+FOXP3+ T-regulatory cells as an immunological marker to differentiate intestinal tuberculosis from Crohn’s disease
Intestinal research
2021 .01
-
Expression of TIM-3, Human β-defensin-2, and FOXP3 and Correlation with Disease Activity in Pediatric Crohn’s Disease with Infliximab Therapy
Gut and Liver
2015 .01
-
Dietary Therapies for Management of Crohn’s Disease
대한외과학회 학술대회 초록집
2022 .11
-
Association of the Genetic Polymorphisms for CD247 Gene and Tuberculosis Case
대한의생명과학회지
2020 .03
-
Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
Intestinal research
2023 .01
-
Pediatric Crohn’s disease with severe morbidity manifested by gastric outlet obstruction: two cases report and review of the literature
Intestinal research
2021 .10
-
Changes in serum levels of lipopolysaccharides and CD26 in patients with Crohn’s disease
Intestinal research
2017 .01
-
Extrinsic Acquisition of CD80 by Antigen-Specific CD8⁺ T Cells Regulates Their Recall Immune Responses to Acute Viral Infection
Immune Network
2019 .08
-
CD5 Expression Dynamically Changes During the Differentiation of Human CD8+ T Cells Predicting Clinical Response to Immunotherapy
Immune Network
2023 .08
-
Oral Symptoms Related to Vitamin B12 Deficiency in a Patient with Crohn’s Disease
Journal of Oral Medicine and Pain
2018 .12
-
Surgery in Pediatric Crohn’s Disease: Indications, Timing and Post-Operative Management
Pediatric Gastroenterology, Hepatology & Nutrition
2017 .01
-
Adalimumab or infliximab: which is better for perianal fistula in Crohn’s disease?
Intestinal research
2017 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0